# IKT (Inhibikase Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Inhibikase Therapeutics, Inc. reported $201.8M in total assets and a net loss of $69.17M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/IKT
- Markdown: https://convexityos.com/fundamentals/IKT.md
- SEC CIK: 0001750149
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:43 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001750149&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$74.90M | Operating profit |
| Net Income | FY 2025 | -$69.17M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.35 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$49.37M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $193.3M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | $0 | $261K | $123K | $3.10M | $698K |
| Research & Development | $29.79M | $17.21M | $13.62M | $12.03M | $11.36M | $894K |
| Selling, General & Admin | $23.56M | $11.38M | $6.73M | $6.22M | $6.51M | $2.62M |
| **Operating Income** | -$51.97M | -$28.59M | -$20.09M | -$18.13M | -$14.77M | -$2.82M |
| **EBITDA** | -$51.91M | -$28.56M | -$19.91M | -$18.12M | -$14.77M | -- |
| Interest Expense | -- | -- | -- | -- | $20K | $29K |
| Income Before Tax | -$48K | -$28K | -- | -- | -- | -- |
| Income Tax Expense | $0 | $0 | -- | -- | -- | -- |
| **Net Income** | -$48.26M | -$27.52M | -$19.03M | -$18.05M | -$14.79M | -$2.85M |
| Basic EPS | -$0.49 | -$1.16 | -$3.16 | -$4.28 | -$4.84 | -$2.09 |
| **Diluted EPS** | -$0.49 | -$1.16 | -$3.16 | -$4.28 | -$4.84 | -$2.09 |
| Basic Shares Outstanding | 98.3M | 23.7M | 6.0M | 4.2M | 3.1M | 1.4M |
| Diluted Shares Outstanding | 98.3M | 23.7M | 6.0M | 4.2M | 3.1M | 1.4M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | $0 | $0 | -- | $0 | $0 | $0 | $0 |
| Research & Development | $15.00M | $13.39M | $10.84M | $6.36M | $7.65M | $5.27M | $10.51M | $7.19M |
| Selling, General & Admin | $7.23M | $7.66M | $7.38M | $6.77M | $5.61M | $5.92M | $5.25M | $5.74M |
| **Operating Income** | -$22.23M | -$21.05M | -$17.84M | -$13.78M | -$12.77M | -$10.83M | -$14.60M | -$12.93M |
| **EBITDA** | -$22.23M | -$21.05M | -$17.84M | -$13.78M | -$12.74M | -$10.81M | -$14.59M | -$12.92M |
| Income Tax Expense | -- | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$20.47M | -$19.59M | -$16.38M | -$12.73M | -$11.93M | -$9.92M | -$13.68M | -$12.13M |
| Basic EPS | -$0.10 | -$0.11 | -$0.10 | -- | -$0.13 | -$0.11 | -$0.15 | -- |
| **Diluted EPS** | -$0.10 | -$0.11 | -$0.10 | -- | -$0.13 | -$0.11 | -$0.15 | -- |
| Basic Shares Outstanding | 196.9M | 174.6M | 172.3M | -- | 90.1M | 90.0M | 89.5M | -- |
| Diluted Shares Outstanding | 196.9M | 174.6M | 172.3M | -- | 90.1M | 90.0M | 89.5M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $178.8M | $97.50M | $9.20M | $7.19M | $40.75M | $13.95M |
| Short-Term Investments | $39.54M | $41.05M | $4.09M | $15.86M | $0 | -- |
| **Cash & Short-Term Investments** | $218.3M | $138.6M | $13.29M | $23.05M | $40.75M | $13.95M |
| **Total Current Assets** | $180.1M | $98.45M | $14.21M | $24.37M | $42.47M | $14.78M |
| Property, Plant & Equipment, Net | $0 | $47K | $73K | $237K | $0 | -- |
| Other Non-Current Assets | $95K | $0 | -- | -- | -- | -- |
| **Total Non-Current Assets** | $1.10M | $149K | $296K | $565K | $0 | $0 |
| **Total Assets** | $181.2M | $98.60M | $14.51M | $24.94M | $42.47M | $14.78M |
| Accounts Payable | $1.16M | $943K | $647K | $1.15M | $1.09M | $1.72M |
| Deferred Revenue (Current) | -- | -- | -- | -- | $0 | $2.33M |
| **Total Current Liabilities** | $8.30M | $3.73M | $3.44M | $3.70M | $4.05M | $4.72M |
| Long-Term Debt | -- | -- | $382K | -- | $249K | -- |
| **Total Non-Current Liabilities** | $0 | $0 | $90K | $205K | $0 | $276K |
| **Total Liabilities** | $8.30M | $3.73M | $3.53M | $3.90M | $4.05M | $5.00M |
| **Total Debt (incl. Leases)** | -- | $111K | $622K | $351K | $249K | -- |
| Common Stock | $132K | $69K | $6.2K | $4.2K | $25K | $10K |
| Retained Earnings | -$142.7M | -$94.42M | -$66.90M | -$47.87M | -$29.82M | $15.03M |
| Accumulated Other Comp. Income | $22K | -$37K | $877 | $105K | $0 | -- |
| **Total Stockholders' Equity** | $172.9M | $94.87M | $10.98M | $21.04M | $38.42M | $9.78M |
| Total Equity | $172.9M | $94.87M | $10.98M | $21.04M | $38.42M | $9.78M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $51.70M | $31.21M | $49.57M | $178.8M | $38.27M | $77.74M | $73.44M | $97.50M |
| Short-Term Investments | $141.6M | $127.8M | $120.8M | $39.54M | $39.05M | $9.92M | $19.74M | $41.05M |
| **Cash & Short-Term Investments** | $193.3M | $159.0M | $170.4M | $218.3M | $77.32M | $87.67M | $93.18M | $138.6M |
| **Total Current Assets** | $198.7M | $162.3M | $172.2M | $180.1M | $78.54M | $88.79M | $94.16M | $98.45M |
| Property, Plant & Equipment, Net | -- | -- | -- | $0 | $0 | $24K | $48K | $47K |
| Other Non-Current Assets | $240K | $245K | $156K | $95K | $58K | -- | -- | $0 |
| **Total Non-Current Assets** | $3.02M | $1.24M | $1.16M | $1.10M | $1.06M | $59K | $117K | $149K |
| **Total Assets** | $201.8M | $163.6M | $173.3M | $181.2M | $79.59M | $88.85M | $94.28M | $98.60M |
| Accounts Payable | $948K | $992K | $1.59M | $1.16M | $621K | $2.70M | $1.69M | $943K |
| **Total Current Liabilities** | $12.96M | $10.26M | $5.71M | $8.30M | $6.70M | $8.80M | $8.55M | $3.73M |
| Other Non-Current Liabilities | $400K | $400K | $400K | -- | -- | -- | -- | -- |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $12.96M | $10.26M | $5.71M | $8.30M | $6.70M | $8.80M | $8.55M | $3.73M |
| **Total Debt (incl. Leases)** | -- | -- | -- | -- | -- | $38K | $75K | $111K |
| Common Stock | $140K | $132K | $132K | $132K | $75K | $75K | $74K | $69K |
| Retained Earnings | -$199.1M | -$178.7M | -$159.1M | -$142.7M | -$129.9M | -$118.0M | -$108.1M | -$94.42M |
| Accumulated Other Comp. Income | -$109K | -$73K | -$26K | $22K | -$4.2K | -$2.9K | -$967 | -$37K |
| **Total Stockholders' Equity** | $188.8M | $153.3M | $167.6M | $172.9M | $72.90M | $80.05M | $85.73M | $94.87M |
| Total Equity | $188.8M | $153.3M | $167.6M | $172.9M | $72.90M | $80.05M | $85.73M | $94.87M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$48.26M | -$27.52M | -$19.03M | -$18.05M | -$14.79M | -$2.85M |
| Depreciation & Amortization | $60K | $26K | $177K | $6.7K | $0 | -- |
| Stock-Based Compensation | $15.31M | $8.14M | $500K | $458K | $1.53M | $574K |
| Change in Receivables | -- | $0 | $40K | -$40K | -$110K | $0 |
| Change in Payables | $147K | $272K | -$504K | $61K | -$631K | -$247K |
| **Operating Cash Flow** | -$27.79M | -$19.15M | -$18.09M | -$17.35M | -$14.30M | -$1.13M |
| Capital Expenditure | -$13K | $0 | -$14K | -$243K | $0 | -- |
| **Free Cash Flow** | -$27.80M | -$19.15M | -$18.10M | -$17.59M | -$14.30M | -- |
| Purchases of Investments | -$39.09M | -$60.46M | -$29.43M | -$20.73M | $0 | -- |
| **Investing Cash Flow** | $2.05M | -$37.00M | $11.66M | -$16.01M | $0 | -- |
| Common Stock Issued | $107.6M | $103.5M | $8.54M | $0 | $0 | $4.9K |
| **Financing Cash Flow** | $108.5M | $103.5M | $8.41M | -$205K | $41.09M | $15.06M |
| **Net Change in Cash** | $82.73M | $47.33M | $1.98M | -$33.56M | $26.80M | $13.94M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$20.47M | -$19.59M | -$16.38M | -$12.73M | -$11.93M | -$9.92M | -$13.68M | -$12.13M |
| Depreciation & Amortization | $0 | $0 | $0 | $0 | $24K | $24K | $13K | $6.6K |
| Stock-Based Compensation | $5.53M | $5.35M | $5.56M | $4.53M | $4.53M | $4.21M | $2.04M | $7.91M |
| Change in Receivables | -- | -- | -- | -- | -- | -- | -- | $0 |
| Change in Payables | -$14K | -$626K | $429K | $538K | -$1.98M | $912K | $681K | -$1.06M |
| **Operating Cash Flow** | -$17.35M | -$12.44M | -$12.06M | -$7.52M | -$10.59M | -$5.57M | -$4.10M | -$5.35M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 | $0 | -$13K | $0 |
| **Free Cash Flow** | -$17.35M | -$12.44M | -$12.06M | -$7.52M | -$10.59M | -$5.57M | -$4.12M | -$5.35M |
| Purchases of Investments | -$75.69M | -$55.03M | -$90.58M | -$99K | -$39.00M | $0 | $0 | -$50.11M |
| **Investing Cash Flow** | -$12.61M | -$5.91M | -$80.48M | -$99K | -$28.75M | $9.84M | $21.05M | -$38.76M |
| Common Stock Issued | $49.11M | $0 | $2.90M | $107.6M | $0 | $150 | $0 | $99.68M |
| **Financing Cash Flow** | $50.46M | -$14K | $2.90M | $108.6M | -$134K | $32K | $0 | $99.68M |
| **Net Change in Cash** | $20.49M | -$18.37M | -$89.65M | $101.0M | -$39.47M | $4.30M | $16.95M | $55.58M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -7712.0% | -14686.2% | -476.2% | -403.5% |
| **Net Profit Margin** | -- | -- | -7304.7% | -14625.9% | -476.9% | -407.7% |
| Return on Equity (ROE) | -27.9% | -29.0% | -173.3% | -85.8% | -38.5% | -29.1% |
| Return on Assets (ROA) | -26.6% | -27.9% | -131.2% | -72.4% | -34.8% | -19.3% |
| Current Ratio | 21.70x | 26.37x | 4.13x | 6.59x | 10.47x | 3.13x |
| Quick Ratio | 26.30x | 37.11x | 3.86x | 6.24x | 10.05x | 2.96x |
| Debt to Equity | -- | 0.00x | 0.06x | 0.02x | 0.01x | -- |
| **Revenue Growth (YoY)** | -- | -100.0% | +111.0% | -96.0% | +343.9% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -36.6% | -39.5% | -30.4% | -27.9% | -65.4% | -51.8% | -42.6% | -29.0% |
| Return on Assets (ROA) | -34.3% | -37.1% | -29.4% | -26.6% | -59.9% | -46.7% | -38.8% | -27.9% |
| Current Ratio | 15.34x | 15.82x | 30.14x | 21.70x | 11.73x | 10.09x | 11.01x | 26.37x |
| Quick Ratio | 14.92x | 15.50x | 29.83x | 26.30x | 11.55x | 9.96x | 10.90x | 37.11x |
| Debt to Equity | -- | -- | -- | -- | -- | 0.00x | 0.00x | 0.00x |
| **Revenue Growth (YoY)** | -- | -- | -- | -- | -- | -- | -- | -100.0% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
